GATC Biotech subsidiary LifeCodexx has updated its noninvasive sequencing-based PrenaTest for fetal trisomies so that it can be performed in high-risk pregnancies as early as nine weeks. The company incorporated a technology dubbed QuantYfeX, which it uses to measure the amount of cell-free fetal DNA in the mother's blood. The PrenaTest can be performed when cffDNA is above 4 percent.
New Products: LifeCodexx's PrenaTest
Jul 10, 2013